In cancer cells, heat shock proteins (HSP), acting as tumor rejection antigens, can form protein complexes with various deranged intracellular proteins and induce CD4+ and CD8+ T cell responses, suggesting that vaccines against HSP will play a role in immunotherapy for GC (16). This evidence concerns the gene HSP90B2P and neoplasm.